Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Johnson & Johnson (JNJ) vs JPMorgan Chase & Co (JPM) Price & Performance

Johnson & JohnsonTrade
JPMorgan Chase & CoTrade

Price performance (Past 24H)

Key statistics

Johnson & Johnson vs JPMorgan Chase & Co — how do they compare? Johnson & Johnson trades at $260.57 (market cap $626.09B), while JPMorgan Chase & Co trades at $364.77 (market cap $962.37B). The key difference: JPMorgan Chase & Co is the larger of the two by market cap, and Johnson & Johnson pays the higher dividend (2.06%). Which is the better fit depends on your goals.

JNJJPM
Market Cap
$626.09B$962.37B
Volume
6,156,22810,479,943
Sector
HealthFinancials
52-Week High
$267.24$362.04
52-Week Low
$172.78$282.84
Enterprise Value
$654.37B
Dividend Yield
2.06%1.66%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Johnson & Johnson

Johnson & Johnson (JNJ) trades at $261.26, down 0.21% on the day, near its 52-week high. The stock shows a bullish technical trend with strong moving averages and recent earnings beats. Revenue grew to $94.19B in 2025, with a net income margin of 21.48%, though cash flow turned negative due to heavy investing. The company maintains a robust dividend history, with consistent payouts and a 64-year growth streak.

Outlook remains positive with a consensus price target of $284.50, offering ~9% upside. Risks include legal headwinds and patent expirations, but analyst sentiment is bullish (52.5% buy ratings). JNJ's defensive profile and pipeline strength support long-term growth, though investors should monitor debt levels, which rose to 24.06% of assets in 2025.

JPMorgan Chase & Co

JPMorgan Chase & Co. (JPM) trades at $365.11, up 1.48% in 24 hours, with a bullish technical signal and strong fundamentals including a 33.38% net income margin and 18.43% ROE. Recent earnings beat expectations in Q1 and Q2 2026, while analyst consensus is a Moderate Buy with a $374.18 price target. CEO Jamie Dimon's shareholder letter highlights economic risks, but institutional buying and resilient sector performance support optimism.

The outlook for JPM is positive, driven by earnings momentum and sector strength, though risks include geopolitical tensions and potential economic headwinds noted by management. Upside to the consensus target offers opportunity, but investors should weigh high RSI levels and macroeconomic cautions.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Johnson & Johnson

Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.

Read more on JNJ

About JPMorgan Chase & Co

JPMorgan Chase & Co. provides global financial services and retail banking. The Company provides services such as investment banking, treasury and securities services, asset management, private banking, card member services, commercial banking, and home finance. JP Morgan Chase serves business enterprises, institutions, and individuals.

Read more on JPM